Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting

Thomas J. Kiernan, Bryan P. Yan, Ignacio Cruz-Gonzalez, Roberto J. Cubeddu, Angel Caldera, Gareth D. Kiernan, Vishal Gupta

Research output: Contribution to journalReview articlepeer-review

Abstract

Angioplasty and stenting have become routine practice for the treatment of significant obstructive atherosclerotic vascular disease. This method of revascularization has a longer history concerning coronary artery disease but is becoming an increasingly used modality of revascularization in the peripheral circulation. Neointimal formation is the pathological basis for restenosis after revascularization procedures such as angioplasty, stenting, and bypass grafting. While restenosis is less of a problem in the coronary circulation with the advent of drug-eluting stents, it continues to be a problem however in the peripheral arterial system. Current treatments to prevent restenosis include pharmacologic, mechanical and cellular approaches which we will discuss in this manuscript.

Original languageEnglish
Pages (from-to)116-124
Number of pages9
JournalCardiovascular and Hematological Agents in Medicinal Chemistry
Volume6
Issue number2
DOIs
Publication statusPublished - Apr 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting'. Together they form a unique fingerprint.

Cite this